Nicorette launch features Facebook contest with Dr. Drew

Share this article:
Nicorette launch features Facebook contest with Dr. Drew
Nicorette launch features Facebook contest with Dr. Drew

GlaxoSmithKline is launching a Nicorette lozenge with a new iteration of the “Quitting Sucks” ad campaign and a Facebook contest starring TV shrink Dr. Drew Pinsky.

The Nicorette Mini Lozenge features a “discreet pocket-size vial,” not dissimilar to the packaging for Mentos. GSK boasts that the lozenge, GSK's first, “dissolves up to three times faster than other stop smoking lozenges and can double a smoker's chances of successfully quitting versus placebo.”

In the TV ad, by TBWA\Chiat\Day, a man in the throes of a nicotine fit sits on a pier, gazing dully out at the water and mumbling “cigarette, cigarette, cigarette.” He proceeds to do so after a shark jumps out of the water and latches onto his arm, oblivious to all but his addiction until he pops a Nicorette Mini Lozenge, whereupon he screams “Shark!” and punches the critter with his free hand.

The company has built a Facebook page for the brand and is launching a “Mini Moments” contest, where smokers can submit their top reason for wanting to quit for a chance to win a trip to LA for a taping of Dr. Pinsky's Loveline and a free course of the lozenges. The page also features short video clips with Pinsky's tips for quitting. Though best known for Loveline, Pinsky is an addiction expert who has featured in the VH1 shows Celebrity Rehab and Sober House.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.